Format

Send to

Choose Destination
Allergy. 2018 Jan;73(1):29-36. doi: 10.1111/all.13239. Epub 2017 Jul 20.

Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.

Author information

1
Department of Dermatology and Division of Skin Surface Sensing, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
2
Research and clinical center for Yusho and dioxin, Kyushu University Hospital, Kyushu University, Fukuoka, Japan.
3
Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
4
Research Center for Advanced Immunology, Kyushu University, Fukuoka, Japan.

Abstract

Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH 2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH 2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.

KEYWORDS:

T helper 2; atopic dermatitis; interleukin-31; interleukin-31 receptor; pruritus

PMID:
28670717
DOI:
10.1111/all.13239
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center